As of May 27, 2025, Krystal Biotech Inc (KRYS) reports a Gross Margin of 93.09%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of Krystal Biotech Inc's Gross Margin
Over recent years, Krystal Biotech Inc's Gross Margin has shown limited historical data. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 93.09% |
| 2023-12-31 | 93.90% |
This trend highlights how Krystal Biotech Inc manages its operational efficiency and pricing power over time.
Comparing Krystal Biotech Inc's Gross Margin to Peers
To better understand Krystal Biotech Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| Krystal Biotech Inc (KRYS) | 93.09% |
| Kura Oncology Inc (KURA) | 7775.20% |
| Immunovant Inc (IMVT) | 7775.20% |
| Kronos Bio Inc (KRON) | 7775.20% |
| Ocugen Inc (OCGN) | 7775.20% |
| Allovir Inc (ALVR) | 7775.20% |
Compared to its competitors, Krystal Biotech Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.